Indications for tacrolimus anti-rejection therapy in liver allograft recipients

Transplant International : Official Journal of the European Society for Organ Transplantation
S JonasP Neuhaus

Abstract

We reviewed our experience with conversion to Tacrolimus after 600 liver transplantations, performed from September 1988 to March 1995. Conversion to Tacrolimus as an anti-rejection therapy was implemented in 78 patients because of chronic ductopenic rejection (n = 9), early chronic rejection (n = 5), OKT3-resistant cellular rejection (n = 12), steroid-resistant cellular rejection (n = 30), late-onset cellular rejection (n = 10), cellular rejection in patients suffering from cyclosporin malabsorption (n = 5) and uncomplicated cellular rejection (n = 7). Control of rejection was achieved in 72 of 78 patients (92%); 6 patients (18%) were non-responsive. Patient and graft survival were 82% and 77%, respectively. Fourteen patients died almost exclusively from opportunistic infections. Out of the six patients who did not respond to Tacrolimus treatment, four underwent successful retransplantation and two died from infections associated with a poor graft function. Overall, graft loss with or without patient death occurred in 6 of 9 patients undergoing chronic rejection, in 3 of 12 patients with OKT3-resistant cellular rejection, in 6 of 30 patients suffering from steroid-resistant cellular rejection and in one patient each suffering ...Continue Reading

Citations

Dec 6, 2003·The Journal of Allergy and Clinical Immunology·Mark BoguniewiczThomas Hultsch
Mar 10, 2001·Clinics in Liver Disease·D C CroninJ M Millis
Aug 2, 2003·Revista do Hospital das Clínicas·Fabricio Ferreira CoelhoSérgio Mies
Mar 19, 2002·American Journal of Therapeutics·Stanley Martin Cohen
Feb 10, 2009·Clinical Transplantation·Laura LladóAntoni Rafecas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.